Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India

Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India

Bibliographic Details
Main Authors:	Debabrata Barmon, Sharda Patra, Megha Nandwani, Roma Jethani, A. C. Kataki
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2023-10-01
Series:	South Asian Journal of Cancer
Subjects:	Ca125 epithelial ovarian cancer interval debulking surgery neoadjuvant chemotherapy overall survival
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1771444

Similar Items

Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer
by: Lu Qin, et al.
Published: (2018-06-01)

Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer
by: Merlo Sebastjan, et al.
Published: (2021-08-01)

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals
by: Kobal Borut, et al.
Published: (2018-09-01)

Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute
by: Monisha Gupta, et al.
Published: (2020-01-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

Perspectives on Ovarian Cancer 1809 to 2022 and Beyond
by: Frank G. Lawton, et al.
Published: (2022-03-01)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
by: Mengmeng Lyu, et al.
Published: (2022-09-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
by: Mackenzie Cummings, et al.
Published: (2022-04-01)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
by: Shi‐Ping Yang, et al.
Published: (2022-07-01)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
by: Xingyu Liu, et al.
Published: (2023-06-01)

The role of cytoreduction surgery in advanced ovarian cancer (review)
by: R K Tandelov, et al.
Published: (2018-03-01)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
by: Yan Gao, et al.
Published: (2019-09-01)

The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
by: Hyunji Lim, et al.
Published: (2022-06-01)

Prognostic Significance of Log(CA125)/PCI for the Resectability of Epithelial Ovarian Cancer: A Retrospective Study
by: He C, et al.
Published: (2020-03-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

Association between alteration of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer antigen-125 and surgical outcomes in advanced stage ovarian cancer patient who received neoadjuvant chemotherapy
by: Ponganun Tuntinarawat, et al.
Published: (2024-04-01)

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
by: Dengfeng Wang, et al.
Published: (2021-03-01)

Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
by: Ioannis Rodolakis, et al.
Published: (2023-03-01)

A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction
by: Francois Kraus, et al.
Published: (2021-09-01)

CA-125 and Ceruloplasmin Levels in Ovarian Cancer Patients
by: Mangala Hegde, et al.
Published: (2015-09-01)

Development and Validation of a Nomogram to Predict Overall Survival in Stage I–III Colorectal Cancer Patients after Radical Resection with Normal Preoperative Serum Carcinoembryonic Antigen
by: Xuan Dai, et al.
Published: (2023-11-01)

Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer
by: Szymon Piatek, et al.
Published: (2020-09-01)

Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review
by: Allan B. Huang, et al.
Published: (2021-11-01)

Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125
by: Szu-Ting Yang, et al.
Published: (2023-11-01)

The role of minimally invasive surgery in epithelial ovarian cancer treatment: a narrative review
by: Matteo Generali, et al.
Published: (2023-06-01)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
by: G. N. A. Winarno, et al.
Published: (2020-07-01)

Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer
by: Yue Jia, et al.
Published: (2024-02-01)

Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction
by: Diederick De Jong, et al.
Published: (2022-11-01)

Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis
by: Guo Junhong, et al.
Published: (2017-05-01)

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
by: Mengdi Fu, et al.
Published: (2022-01-01)

Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study
by: Dairui Dai, et al.
Published: (2022-02-01)

HIPEC after Interval Debulking Surgery as Best Clinical Practice in Ovarian Cancer Patients: Case Series and Literature Review
by: Stefano Restaino, et al.
Published: (2022-06-01)

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): New Approaches and Controversies on the Treatment of Advanced Epithelial Ovarian Cancer—Systematic Review and Meta-Analysis
by: Luigi Della Corte, et al.
Published: (2023-11-01)

Cisplatin, cyclophosphamide versus taxol, carboplatin in epithelial ovarian carcinoma: a clinical trial
by: Modarres M, et al.
Published: (2007-05-01)

The Effect of Delayed Chemotherapy on the Decrease of CA125 in Epithelial Ovarian Cancer During Coronavirus Disease Pandemic in 2020
by: Yi Q, et al.
Published: (2021-01-01)

"CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA?"
by: M. Modarres-Gilani, et al.
Published: (2004-12-01)

"CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA?"
by: M. Modarres-Gilani, et al.
Published: (2004-11-01)